Workflow
Ningbo Tianyi Medical Appliance (301097)
icon
Search documents
宁波天益医疗器械股份有限公司关于开立募集资金专项账户并签署募集资金三方监管协议的公告
Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced a change in the use of raised funds, terminating the original project for the "Comprehensive R&D Center Construction Project" and reallocating the remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Fundraising Basic Information - The company raised a total of RMB 771.77 million by issuing 14.7368 million shares at RMB 52.37 per share, with net proceeds amounting to RMB 694.56 million after deducting various fees [1]. - The funds were verified by Lixin Accounting Firm, which issued a verification report [1]. Fundraising Special Account and Supervision Agreement - The company has established a special fundraising account at Shanghai Pudong Development Bank, Ningbo High-tech Zone Branch, for the new project [2][3]. - The company has signed a tripartite supervision agreement with the bank and its sponsor, Guotai Junan Securities, to oversee the use of the raised funds [3][4]. Tripartite Supervision Agreement Key Points - The special accounts for RMB and USD have been established, with balances of RMB 108.29 million and USD 0 as of July 2, 2025 [4]. - The funds in these accounts are exclusively for the "Thailand Production Base Construction Project" and cannot be used for other purposes [4]. - The sponsor has the right to supervise the use of funds and can conduct on-site investigations and inquiries [5][6]. - Any withdrawal exceeding RMB 20 million within a 12-month period must be reported to the sponsor [6].
天益医疗(301097) - 关于开立募集资金专项账户并签署募集资金三方监管协议的公告
2025-07-04 08:36
宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 证券代码:301097 证券简称:天益医疗 公告编号:2025-038 并签署募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司(以下简称"天益医疗"或"公司")于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》,同意变更募集资金用途,同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目",并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目";同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日,公司已完成部分募集资金专项账户的开立及募集资金三 方监管协议的签署,具体情况如下: 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发行股票注册的批复》(证监许可 ...
天益医疗(301097) - 关于公司新产品取得产品注册证书的公告
2025-06-05 07:42
证券代码: 301097 证券简称:天益医疗 公告编号:2025-037 宁波天益医疗器械股份有限公司 特此公告。 宁波天益医疗器械股份有限公司董事会 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一次性使用连续 | 国械注准 | | 2025 | 年 5 | 月 | 30 | 日至 | 供连续性肾脏替 代治疗(CRRT) 时作为血液及液 | | 1 | 性肾脏替代治疗 | 2025310111 | III | | | | | | | | | 管路 | 2 | | 2030 | 年 | 月 5 | 29 | 日 | | | | | | | | | | | | 体通道使用。 | | 2 | | | | | | | | | 用于急、慢性肾功 能衰竭患者的血 | | | | | | | | | | | 液透析、血液透析 | | | 一次性使用血液 | 国械注准 | III | 2025 | 年 5 | 月 | 30 | 日至 ...
宁波天益医疗器械股份有限公司2024年年度权益分派实施公告
Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of 5.00 RMB per 10 shares (including tax) for shareholders, with no bonus shares or capital reserve conversion [2][3][4]. Summary by Sections Profit Distribution Plan - The company will distribute cash dividends based on a total share count of 57,519,968 shares after excluding 1,427,400 shares repurchased [2][3]. - The total cash dividend to be distributed amounts to 28,759,984 RMB [3]. Dividend Calculation - The cash dividend per 10 shares is calculated as follows: [(58,947,368 - 1,427,400) / 10 * 5] / 58,947,368 * 10 = 4.878925 RMB per 10 shares [4][9]. - The reference price for ex-dividend trading will be adjusted by subtracting the cash dividend per share from the closing price on the day before the ex-dividend date [9]. Key Dates - The record date for the dividend distribution is set for May 15, 2025, and the ex-dividend date is May 16, 2025 [5][6]. Dividend Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies on the ex-dividend date [7]. - The company will bear all legal responsibilities if there are any discrepancies in the dividend distribution due to changes in shareholders' accounts during the application period [8].
天益医疗(301097) - 2024年度权益分派实施公告
2025-05-12 10:38
证券代码:301097 证券简称:天益医疗 公告编号:2025-036 宁波天益医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 宁波天益医疗器械股份有限公司(以下简称"公司")2024 年年度股东会审 议并通过了《关于 2024 年度利润分配预案的议案》。根据《中华人民共和国公司 法》《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规定, 本公司回购专用证券账户中的 A 股股份不参与 2024 年度权益分派。公司以现有 总股本 58,947,368 股剔除已回购股份 1,427,400 股后的总股数 57,519,968 股 为基数,每 10 股送红股 0 股,资本公积金转增股本 0 股,派发现金 5.00 元(含 税)。 本次权益分派实施后,按公司总股本折算每 10 股现金红利及除权除息参考 价计算如下:按公司总股本(含回购股份)折算的每 10 股现金分红(含税)=本 次实际现金分红总额/公司总股本*10 股=[(58,947,368-1,427,400)/10*5]元 /58,947,368 股*10 股= ...
天益医疗(301097) - 2024年年度股东会法律意见书
2025-05-06 10:12
关于宁波天益医疗器械股份有限公司 2024 年年度股东会的法律意见书 上海璟和律师事务所 致:宁波天益医疗器械股份有限公司 宁波天益医疗器械股份有限公司(以下简称"公司")2024 年年度股东会 于 2025 年 5 月 6 日(星期二)下午 13:00 在浙江省宁波市东钱湖旅游度假区莫 枝北路 788 号宁波天益医疗器械股份有限公司会议室如期召开。上海璟和律师 事务所经公司聘请,委派徐艺嘉律师、梅彦律师列席现场会议,根据《中华人 民共和国公司法》(以下简称"《公司法》")、《上市公司股东会规则》 (以下简称"《股东会规则》")等有关法律、行政法规、部门规章、规范性 文件以及《宁波天益医疗器械股份有限公司章程》(以下简称"《公司章 程》")、《宁波天益医疗器械股份有限公司股东大会议事规则》(以下简称 "《议事规则》")的规定,就本次股东会的召集和召开程序、召集人及出席 会议人员的资格、会议议案、表决方式和表决程序、表决结果和会议决议等出 具本法律意见书。 在本法律意见书中,本所律师仅对本次股东会的召集和召开程序、出席会 议人员的资格、召集人资格、会议表决程序及表决结果是否符合《公司法》 《股东会规则》《公司章 ...
天益医疗(301097) - 2024年年度股东会决议公告
2025-05-06 10:12
2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 证券代码: 301097 证券简称:天益医疗 公告编号:2025-035 宁波天益医疗器械股份有限公司 特别提示: 1、本次股东会无增加、变更、否决提案的情况; 2、本次股东会以现场投票和网络投票相结合的方式召开; 3、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况: 1、会议召集人:宁波天益医疗器械股份有限公司董事会 2、召开方式:本次股东会采用现场投票与网络投票相结合的方式召开 3、会议召开时间 (1)现场会议时间:2025 年 5 月 6 日 13:00 (2)网络投票时间:2025 年 5 月 6 日 ① 通过深圳证券交易所交易系统进行投票的具体时间为:2025 年 5 月 6 日 9:15-9:25,9:30-11:30 和 13:00-15:00; ② 通过深圳证券交易所互联网投票系统投票的具体时间为:2025 年 5 月 6 日 9:15 至 2025 年 5 月 6 日 15:00 期间的任意时间。 4、现场会议召开地点:浙江省宁波市东钱湖旅游度假区 ...
天益医疗(301097) - 关于公司新产品取得产品注册证书的公告
2025-04-30 07:44
证券代码: 301097 证券简称:天益医疗 公告编号:2025-034 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司(以下简称"公司")于近日收到浙江省药 品监督管理局颁发的《医疗器械注册证》,具体情况如下: 一、产品注册证具体情况 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一次性使用肠内 | 浙械注准 | II | | | | | | 产品与肠营养器、 经鼻肠营养导管、 | | | | | | | | | | | 经皮肠营养导管 | | | | | | 2025 | 年 4 | 月 | 27 | 日至 | | | | 营养注射器 | 20252141312 | | | 年 | | 月 | 日 | 等营养管路配套 | | | | | | 2030 | | 4 | ...
天益医疗(301097) - 301097天益医疗投资者关系管理信息20250429
2025-04-29 13:17
Group 1: Financial Performance - In 2024, the company achieved a revenue of 418.96 million CNY, representing a year-on-year growth of 9.98% [3] - The net profit for 2024 was -0.744 million CNY, indicating a loss compared to the previous year [3] - The company plans to distribute cash dividends of 5.00 CNY per 10 shares, totaling approximately 28.76 million CNY, despite the negative net profit [8] Group 2: Cost and Expense Management - Management expenses increased by 45.39% and sales expenses rose by 31.25% in 2024 due to rapid growth in personnel [3] - R&D expenses surged by 94.47%, reflecting the company's commitment to innovation and development [6] Group 3: Market and Business Strategy - The company has a foreign sales ratio of approximately 38%, with no significant impact from current tariff policies on completed orders [2] - The construction of the Thailand factory is progressing as planned, with an expected operational start in 2026 [3] - The company is focusing on expanding its market presence both domestically and internationally, particularly in South America [5] Group 4: Product Development and Innovation - The company is actively developing new products, including dialysis solutions and CRRT products, to enhance its product portfolio [4] - The company has acquired CRRT business assets and plans to complete a comprehensive business ecosystem within three years [4] Group 5: Industry Outlook - The medical device industry, particularly in blood purification, is expected to grow due to increasing global end-stage renal disease patients and supportive national policies [6] - The company remains optimistic about the future of the industry, citing the essential nature of its products and the relatively low impact of market fluctuations [6]
宁波天益医疗器械股份有限公司第三届董事会第二十四次会议决议公告
Group 1 - The company held its 24th meeting of the third board of directors on April 25, 2025, with all 7 directors present, including one via telecommunication [2][4] - The board unanimously approved the proposal regarding the 2025 Q1 report, confirming that the report accurately reflects the company's operational status without any false records or significant omissions [3][5] - The proposal does not require submission to the shareholders' meeting for approval [6] Group 2 - The company also held its 20th meeting of the third supervisory board on April 25, 2025, with all 3 supervisors present [11][13] - The supervisory board unanimously approved the proposal regarding the 2025 Q1 report, affirming that the report is accurate and complies with legal requirements [11][12] - The decision of the supervisory board is legally valid as it met the quorum requirements [11][13]